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Introduction
Bronchial hyperresponsiveness (BHR) is one of  pathophysiologi-
cal features usually associated with chronic inflammation and re-
versible obstruction of  airways in patients with asthma [1]. This 
phenomenon is also found out in the pathogenesis of  chronic ob-
structive pulmonary disease (COPD) and known as a risk factor 
for the development of  respiratory symptoms as well as a predic-
tor for lung functional impairment [2]. Clinically, BHR is defined 
by excessive bronchospasm responding to a specific or nonspe-
cific stimulus. The use of  methacholine to produce bronchocon-
striction is the most common method for assessing the increase 
of  bronchial responsiveness [3]. Methacholine is a chemical prod-
uct that acts directly on smooth muscle cells producing bronchial 
constriction. The test of  methacholine challenge is based on an 
association of  increasing inhaled concentrations of  methacholine 
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and a repetitive measurements of  FEV1 (forced expiratory vol-
ume in one second) with the drop of  FEV1 more than 20%.
Methacholine challenge is useful for diagnosis of  asthma [4], es-
pecially in patients without clinical symptom of  asthma or with-
out abnormalities in lung function measured by spirometry or 
whole body plethysmography. However, until now, the use of  
methacholine challenge to find out BHR for diagnosis of  asthma 
is still not available in some medical centers, even though in some 
national hospital of  respiratory diseases in developing countries. 
Moreover, methacholine challenge may produce severe bronchos-
pasm in some patients and should be avoided in some clinical 
situations such as pregnant women or patients with severe cardio-
vascular diseases.
Recently, exhaled nitric oxide (NO) has been used as a biomarker 
of  asthma because the concentration of  NO in exhaled breath 
is significantly correlated with the level of  inflammation in the 
airways [5]. The measure of  NO in exhaled breath (FENO) is a 
non-invasive method for evaluating an allergic inflammation and 
plays an important role in the diagnosis and control of  asthma [5-
7]. In asthma, although FENO correlates significantly with other 
biomarkers of  inflammation such as eosinophil count in sputum 
or total IgE in serum, the correlation between FENO and BHR 
is still controversial. It is due to the contradictory correlation 
between the level of  bronchial FENO and the dose of  metha-
choline to reduce 20% of  FEV1 (PD20 - methacholine). Some 
authors found there was a significant correlation, while the oth-
ers described no significant association [8-10]. These conflicting 
results might be explained by certain differences in study popula-
tion or FENO measurement method.
Objectives
This study was planned to describe: 1) Level of  exhaled NO in 
subjects with bronchial hyperresponsiveness (BHR) diagnosed by 
methacholine challenge; 2.) Correlation between the level of  ex-
haled NO and the dose of  methacholine in subjects with positive 
BHR. 3) Cute-off  of  exhaled NO for diagnosing BHR in study 
population.
Subjects and Methods
Study Subjects
It was a cross-sectional and descriptive study. Subjects who had 
been realized a methacholine challenge for diagnosis of  BHR at 
Clinical Research Unit of  Lam Dong Medical College were in-
cluded in the study after signing an Institutional Review Board-
approved consent form. These subjects had one of  following 
symptoms with suggestive asthma were included in the study: 
chronic or nocturnal cough, wheezing or chest tightness at night 
or during physical exercise.
Subjects who were active smokers in the last 5 years or used any 
inhaled corticosteroids (ICS) or systemic corticosteroids for less 
than 3 months were excluded from the study. All bronchodilators 
had been interrupted for at least 24 hours before all the tests. 
Subjects had any contraindication for methacholine challenge 
such as cardiovascular diseases, seizures, pregnancy, uncontrolled 
high blood pressure, or recent respiratory infection were excluded 
from the study. FENO measurement was made routinely before 
methacholine challenge testing.
Laboratory Techniques
Lung Function Test (LFT): LFT was done by using whole-
body phlethysmography with Body Box 500 (Medisoft, Sorinnes, 
Belgium). The Body Box had been calibrated every day by using 
a standard three liter pump. Each study subject beneficed three 
best flow - volume curves for FEV1 and all values were selected 
in accordance with the ATS (American Thoracic Society)/ERS 
(European Respiratory Society) recommendations [11]. The data 
was presented as percentage of  theoretical normal values.
Measurement of  Exhaled NO: Exhaled NO was measured 
at multiple flow rates (50 mL/s, 100 mL/s, 150 mL/s, and 350 
mL/s) before methacholine challenge by using an electrochemical 
based analyzer FeNO+ (Medisoft, Sorinnes, Belgium). Technical 
measurement of  exhaled NO was conducted according to manu-
facturer’s instructions, as recommended by the ATS/ERS guide-
line [6]. The maximal bronchial production rate of  NO (J’awNO) 
and alveolar concentration of  NO (CANO) were automatically 
determined using the two-compartment model and had been re-
ported via Expair’s software (Medisoft) as described previously 
[12, 13].
Methacholine Challenge: Methacholine (acetyl methylcholine 
chloride) was used in the form of  5% concentration solution. 
Prior to each test, 2.5% solution of  methacholine was prepared 
by diluting a stock solution in 2 mL of  saline buffer (NaCl 0.9%). 
Study subject was in sitting posture, using nose clip and oral in-
halation from an aerosol spray device integrated in Body Box 500 
and it was automatically activated by computer software. After 
initial measurement with methacholine - free diluted saline, in-
halation of  methacholine through multiple steps at double dose 
steps was starting at 100 mcg up to a maximum cumulative dose 
of  3,100 mcg.
FEV1 value was measured at 60 seconds after each step and the 
lowest value was recorded. The methacholine challenge had been 
stopped when FEV1 dropped more than > 20% of  baseline or 
after reaching the maximum dose. All study subjects were given 
systematically 400 mcg of  Ventolin inhalation after methacholine 
challenge and remained in the waiting room until their FEV1 val-
ues returned to above 90% of  the initial values. The accumulated 
dose of  methacholine causing 20% reduction of  FEV1 (PD20 
- methacholine) was calculated from linear equation of  response 
curve - dose. BHR was positive when there was a decrease of  
FEV1 ≥ 20% with methacholine dose ≤ 3,100 mcg.
Statistical Analysis: Statistical analysis was performed by using 
SPSS software (version 22.0; Chicago IL; USA). Values were ex-
pressed as mean ± standard deviation for quantitative variables 
and percentage for qualitative variables. The comparison between 
groups was done by Student’s t-test. The Pearson coefficient was 
used to evaluate the correlation between parameters and statisti-
cal significance as determined by P value < 0.05. The ROC curve 
was used to evaluate the predictive value of  FENO for diagnosis 
of  BHR.
Results
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Clinical Characteristics of  Study Subjects Classified by 
Negative or Positive BHR
Ninety-five subjects were included in this study. They were di-
vided into two groups: 64 subjects with negative BHR and 31 
others with positive BHR. There were no significant differences 
between two groups for age and male/female ratio (41 ± 22 vs 38 
± 23 years old and 0.9 vs 1.1; P > 0.05 and P > 0.05; respectively; 
Table 1). The body mass index (BMI) did not differ between two 
groups (22 ± 6 vs 23 ± 5; P > 0.05). Concerning suspected symp-
toms of  asthma, there were no significant differences between 
two groups for the percentage of  tightness of  chest and chronic 
cough (62.5% and 78.1% vs 64.5% and 80.6%; P > 0.05 and P > 
0.05; Table 1).
The percentage of  wheezing and nocturnal coughing in subjects 
with positive BHR was significantly higher than that in subjects 
with negative BHR (70.9% and 64.5% vs 31.2% and 45.1%; P < 
0.001 and P < 0.01; respectively; Table 1). In subjects with posi-
tive BHR, the percentage of  subjects had a familiar asthma or an 
atopy was higher than that in those with negative BHR (P < 0.01 
and P < 0.01; respectively; Table 1).
Functional Characteristics of  Study Subjects Classified by 
Negative or Positive BHR
The results of  present study showed that there were no significant 
differences between two groups for lung function parameters 
(Table 2). The mean percentage of  FEV1 and FEV1/FVC ratio 
was not significantly different between subjects with negative or 
positive BHR (102 ± 14% and 81 ± 12% vs 101 ± 13% and 78 
± 11%; P > 0.05 and P > 0.05; respectively; Table 2). The dose 
of  methacholine using for provocation test to diagnosis negative 
or positive BHR was significantly different between two groups 
(3,100 mcg for negative BHR vs 1,640 mcg for positive BHR; P <
0.001). The fall of  FEV1 in subjects with positive BHR was sig-
nificantly higher than that for those with negative BHR (32 ± 8% 
vs 12 ± 6%; P < 0.01; Table 2).
The result of  exhaled NO measurement showed that the levels 
of  FENO measured at 100 mL/s - 150 mL/s - 350 mL/s were 
not significant differences between subjects with negative BHR 
and positive BHR (P > 0.05, P > 0.05, and P > 0.05; respectively; 
Table 2). The level of  FENO measured at 50 mL/s in subjects 
with positive BHR was significantly higher than that in subjects 
with negative BHR (36 ± 10 ppb vs 11 ± 9 ppb; P < 0.001; Ta-
ble 2). There was no significant difference between CANO levels 
between positive and negative BHR (3 ± 2 ppb vs 2 ± 1 ppb; P 
> 0.05; Table 2).
Correlation between Methacholine Dose and FENO Level 
in Subjects with Positive BHR
The linear regression equation between the dose of  methacho-
line and the level (concentration) of  FENO with the flow of  50 
mL/s (bronchial level) in subjects with positive BHR showed that 
there was a significant correlation between these two parameters 
(Figure 1). This correlation was negative and strong (R = - 0.695; 
P < 0.001; Figure 1). The multivariate regression analysis showed 
the correlation between methacholine dose and FENO was inde-
pendent with anthropometric parameters (age, gender, height or 
weight, and BMI; data not showed) and lung function parameters 
(FEV1, FVC, and TLC; data not showed).
Table 1. Clinical characteristics of  study subjects classified by negative or positive BHR.
Parameters BHR (-)(N = 64)
BHR (+)
(N = 31) P
Anthropometry
Age, years (min-max) 41 ± 22
(18 - 64)
38 ± 23
(18 - 65)
NS
Male/Female, ratio 15/170.9
16/15
1.1 NS
Height, cm 161 ± 9
(152 - 172)
162 ± 7
(150-173)
NS
Weight, kg (min-max) 58 ± 13
(50 - 72)
59 ± 12
(53 - 76)
NS
BMI, kg/m2(min-max) 22 ± 6
(18 - 28)
23 ± 5
(17 - 27)
NS
Symptoms
Wheezing, % 31.2 70.9 < 0.001
Tightness of  chest, % 62.5 64.5 NS
Chronic cough, % 78.1 80.6 NS
Nocturnal coughing, % 45.1 64.5 < 0.01
Medical History
Familiar asthma, % 12.5 32.2 < 0.01
Atopy, % 14.1 35.4 < 0.01
BHR: bronchial hyperresponsiveness; BMI: body mass index; NS: no significant difference; (-): negative; (+): positive
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Cute-off  of  FENO Level for Screening Subjects with Posi-
tive BHR
The receiver operating characteristic (ROC) curve of  FENO 
level measured at 50 mL/s in subjects with positive BHR was 
performed to measure the sensitivity and specificity of  different 
levels of  FENO for screening positive BHR (Figure 2). The level 
of  FENO at 35 ppb had a highest Youden’s Index (or highest 
area under curve) with 86.7% of  sensibility and 82.9% of  speci-
ficity (Figure 2 and Table 3). With the level of  FENO at 38 ppb, 
the sensitivity and specificity was 78.2% and 89.6%, respectively 
(Figure 2 and Table 3).
Discussion
Currently, the relationship between FENO and BHR identified 
by methacholine challenge is still controversial. In this study, the 
correlation between the dose of  methacholine causing significant 
bronchoconstriction (PD20 - methacholine) and the concentra-
tion of  NO in exhaled breath (FENO) measured at 50 mL/s has 
been demonstrated (Figure 1). Especially, FENO level of  subjects 
with positive BHR (BHR+) was significantly higher than that for 
those with negative BHR (BHR-; Table 2). In addition, subjects 
with BHR (+) had the percentages of  wheezing, nocturnal cough-
ing, familiar asthma, and atopy were significantly higher than sub-
jects with BHR (-). It suggests that these clinical symptoms might 
be used as markers of  BHR.
In subjects with asthma, BHR is often present and considered as 
one of  the features of  this disease. In asthma, FENO is also in-
creased and similar with chronic airways inflammation and associ-
ated with hypereosinophilic. According to current recommenda-
tions, FENO can be used to diagnose and monitor the treatment 
of  asthma [14, 15]. In patients with atypical symptoms of  asthma, 
presented by chronic cough, wheezing, nocturnal coughing, or 
dyspnea during exertion, methacholine challenge is a relevant and 
helpful tool to determine the persistence of  non-specific bron-
chial responsiveness and then to confirm the diagnosis of  asthma.
The present study suggests that FENO level measured at 50 
Table 2. Functional characteristics of  study subjects classified by negative or positive BHR.
Parameters BHR (-)(N = 64)
BHR (+)
(N = 31) P
Lung Function
FVC, % 104 ± 16(91 - 123)
103 ± 17
(88 - 125)
NS
TLC, % 108 ± 13
(88 - 128)
112 ± 14
(89 - 128)
NS
FEV1, %
102 ± 14
(89 - 122)
101 ± 13
(86 - 127)
NS
FEV1/FVC, %
81 ± 12
(72 - 94)
78 ± 11
(70 - 86)
NS
PEF, % 104 ± 17
(89 - 134)
102 ± 18
(86 - 136)
NS
FEF25-75, % 83 ± 21
(56 - 118)
81 ± 17
(54 - 115) NS
Methacholine Challenge
Methacholine dose, mcg 3,100 1.640 ± 1.280(100 – 3.100) < 0.001
Fall of  FEV1, %
12 ± 6
(6 – 17)
32 ± 8
(22 – 45) < 0.01
Exhaled NO
FENO at 50 mL/s, ppb 11 ± 9(3 - 20)
36 ± 10
(18 - 69)
< 0.001
FENO at 100 mL/s, ppb 13 ± 11(5 - 25)
15 ± 12
(19 - 72)
NS
FENO at 150 mL/s, ppb 9 ± 6(4 - 22)
11 ± 8
(5 - 23) NS
FENO at 350 mL/s, ppb 7 ± 6
(3 - 18)
8 ± 7
(2 - 14) NS
J’awNO, nL/min 24 ± 15(11 - 43)
25 ± 17
(10 - 44) NS
CANO, ppb 2 ± 1(1 - 5)
3 ± 2
(1 - 5) NS
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; TLC: total lung capacity; PEF: peak expiratory flow; FEF25-75: forced 
expiratory flow at 25-75% of  time; FENO: fractional exhaled nitric oxide (measured at expiratory flows of  50, 100, 150, and 350mL/s); CANO: 
alveolar concentration of  nitric oxide; J’awNO: maximal bronchial flux of  nitric oxide (using the two-compartment model). BHR: bronchial hyperre-
sponsiveness; NS: no significant difference; (-): negative; (+): positive.
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Figure 1. Correlation between methacholine dose and FENO (fractional exhaled nitric oxide) level measured at 50 mL/s in 
subjects with positive BHR (bronchial hyperresponsiveness).
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Figure 2. Receiver Operating characteristic (ROC) curve of  FENO measured at 50 mL/s for predicting subjects with posi-
tive BHR (bronchial hyperresponsiveness).
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Table 3. Sensitivity and specificity of  FENO level measured at 50 mL/s in subjects with positive BHR.
FENO level with BHR (+)
(ppb)
Sensitivity
(%)
Specificity
(%)
21 90.7 69.4
24 89.9 72.7
26 89.3 75.3
32 88.4 79.8
35 86.7 82.9
36 83.4 86.1
38 78.2 89.6
41 75.2 91.2
43 72.8 91.6
45 72.3 93.3
50 69.8 94.7
FENO: fractional exhaled nitric oxide; BHR (bronchial hyperresponsiveness); (+): positive.
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mL/s may be used as a biomarker for diagnosis of  BHR. FENO 
measured at 50 mL/s (FENO - 50 mL/s) is used currently to 
evaluate the bronchial inflammation in subjects with asthma [6, 
15, 16]. In adult, the normal level of  FENO measured at 50 mL/s 
is lower than 25 ppb. The result of  our study showed that FENO 
– 50 mL/s ≥ 35 ppb can be used to diagnose BHR because of  its 
high sensitivity and high specificity (Figure 2 and Table 2). How-
ever, when using the high level of  FENO, there was a significant 
decrease of  sensitivity and increase of  specificity. Inversely, the 
sensitivity of  FENO level to diagnose BHR was decreased when 
the level of  FENO between 25 - 35 ppb (Table 3).
Measuring exhaled NO is easier to realize than methacholine chal-
lenge testing. This technique is safer than methacholine challenge 
to determine BHR. Actually, the use of  portable of  FENO meas-
urement is expanded in many countries. FENO is also a good 
biomarker to diagnose asthma and to follow-up asthma control 
[17-20]. Whereas, methacholine is a chemical product and not 
available in some areas and countries with low resources. Moreo-
ver, the result of  our study suggests that in some situations and 
in subjects with contraindications of  methacholine challenge 
such pregnant women or subjects with severe cardiovascular dis-
eases, the measure of  FENO may be an alternative method to 
screen out BHR. Finally, methacholine challenge does not seem 
to be necessary to be done in subjects with high level of  FENO 
(positive prediction) or low level of  FENO (negative prediction). 
However, more studies on the correlation between FENO and 
BHR in subjects with atypical symptoms of  asthma should be 
realized in the future to clarify the role of  FENO in diagnosis of  
BHR [21].
Conclusion
Bronchial hyperresponsiveness (BHR) is one of  asthma features. 
The present of  BHR is useful for clinicians to diagnose asthma in 
subjects with atypical symptoms. However, the use of  methacho-
line challenge to confirm BHR is not available in some respiratory 
centers and unsafe in some clinical settings. Hence, the measure 
of  FENO is a relevant alternative method to screen out BHR in 
subjects with suspected symptoms of  asthma.
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